People: GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

46.59USD
24 Apr 2015
Change (% chg)

$0.28 (+0.60%)
Prev Close
$46.31
Open
$46.23
Day's High
$46.80
Day's Low
$46.12
Volume
3,279,134
Avg. Vol
3,463,873
52-wk High
$56.48
52-wk Low
$41.25

Search Stocks

Summary

Name Age Since Current Position

Christopher Gent

66 2005 Non-Executive Independent Chairman of the Board

Andrew Witty

50 2008 Chief Executive Officer, Executive Director

Philip Hampton

61 2015 Non-Executive Deputy Chairman of the Board

Simon Dingemans

51 2011 Chief Financial Officer, Executive Director

Moncef Slaoui

55 2014 Chairman - Global Vaccines, Executive Director

Roger Connor

2013 President - Global Manufacturing & Supply

Shah Abbas Hussain

49 2012 President - Europe, Japan & EMAP

Patrick Vallance

2012 President - Pharmaceuticals R&D

Emma Walmsley

2011 President - Consumer Healthcare Worldwide

Daniel Troy

2008 Senior Vice President, General Counsel

Claire Thomas

2008 Senior Vice President - Human Resources

Bill Louv

2013 Senior Vice President - Core Business Services

Phil Thomson

2010 Senior Vice President - Global Communications

David Redfern

2008 Chief Strategy Officer

Victoria Whyte

2011 Company Secretary

Roy Anderson

67 2007 Non-Executive Independent Director

Stephanie Burns

60 2007 Non-Executive Independent Director

Stacey Cartwright

51 2011 Non-Executive Independent Director

Tom de Swaan

69 2006 Non-Executive Independent Director

Lynn Elsenhans

58 2012 Independent Non-Executive Director

Judy Lewent

66 2011 Non-Executive Independent Director

Deryck Maughan

67 2013 Senior Independent Non-Executive Director

Daniel Podolsky

61 2006 Non-Executive Independent Director

Urs Rohner

56 2015 Non-Executive Independent Director

Jing Ulrich

47 2012 Independent Non-Executive Director

Hans Wijers

64 2013 Independent Non-Executive Director

Biographies

Name Description

Christopher Gent

Sir Christopher Charles Gent has resigned as Non-Executive Independent Chairman of the Board of GlaxoSmithKline plc., effective 7 May 2015. He has many years of experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. He is a Non-Executive Director of Ferrari SpA, a Senior Adviser at Bain & Co and a member of the British Airways International Business Advisory Board.

Andrew Witty

Sir Andrew Philip Witty is Chief Executive Officer, Executive Director of GlaxoSmithKline PLC. He joined GSK in 1985. He joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. He served as the Lead Non-Executive Board member for the Department of Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until July 2013. Sir Andrew is a member of the UK Prime Minister’s Business Advisory Group and was appointed to the UK Business Ambassador Group in January 2014.

Philip Hampton

Sir Philip Hampton has been appointed as Non-Executive Deputy Chairman of the Board of GlaxoSmithKline PLC., effective May 7, 2015. He has been appointed as an Independent Non-Executive Director of the Company effective January 1, 2015 and Non-Executive Deputy Chairman of the Board effective April 1, 2015. Sir Philip has been Chairman of The Royal Bank of Scotland Group plc (RBS) since February 2009. He was previously Chairman of J Sainsbury plc and Group Finance Director at Lloyds TSB Group, BT Group plc, BG Group plc, British Gas and British Steel plc, an Executive Director of Lazards and a Non-Executive Director at RMC Group plc and Belgacom SA. He is also a former Chairman of UK Financial Investments Limited, which manages the UK Government's shareholdings in banks. Sir Philip is Senior Independent Director of Anglo American plc, Chairman of their Remuneration Committee and member of their Audit Committee. He will leave RBS in 2015.

Simon Dingemans

Mr. Simon Dingemans is Chief Financial Officer, Executive Director of GlaxoSmithKline plc. Prior to joining GSK, Simon has over 25 years of experience in investment banking at SG Warburg and Goldman Sachs. During this time, he advised a broad range of large corporates across a number of industry sectors, including pharmaceuticals and consumer healthcare. Simon advised GSK for over a decade before his appointment and was closely involved in a number of GSK’s key strategic projects. Simon is Chairman of the 100 Group and a member of the Corporate Development Council for the National Theatre.

Moncef Slaoui

Dr. Moncef Slaoui is Chairman - Global Vaccines, Executive Director of GlaxoSmithKline PLC. Dr. Slaoui continue to provide scientific and technical counsel on pharmaceutical R&D activities to the CEO and Board. Dr. Slaoui joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was also given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. He is a member of the PhRMA and the Biotechnology Industry Organization boards in the USA and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011.

Roger Connor

Mr. Roger Connor is President - Global Manufacturing & Supply of Glaxosmithkline PLC., since January 2013. After working for a year as President Designate, GMS. Roger joined GSK in 1998 from AstraZeneca and has worked in a number of roles within finance and manufacturing strategy, including at GSK sites at Cork in Ireland and Ware in the UK. Prior to his role in GMS, Roger was Vice President, Office of the CEO and Corporate Strategy from February 2010. He holds a Degree in Mechanical and Manufacturing Engineering from Queen’s University Belfast and a Masters in Manufacturing Leadership from Cambridge University. He is also a Chartered Accountant.

Shah Abbas Hussain

Mr. Shah Abbas Hussain is President - Europe, Japan & EMAP of GlaxoSmithKline PLC., since September 2012. Abbas joined CET in 2008 and was appointed President, Global Pharmaceuticals in October 2014, having joined the company as President, Emerging Markets & Asia Pacific in June 2008. He joined the ViiV Healthcare Ltd. Board in October 2009 and the Aspen Board in December 2009. Previously, he spent 20 years at Eli Lilly where he held positions including President, Europe and before that Vice President, Europe. He also held positions with Eli Lilly in Australia, the USA, India, Turkey and Germany in several roles including business development, sales and marketing, and management. He has a degree in Medicinal Chemistry & Pharmacology from Loughborough University and was born in Madras, India.

Patrick Vallance

Mr. Patrick Vallance is President - Pharmaceuticals R&D of Glaxosmithkline Plc., since January 2012. Prior to his appointment he was Senior Vice President, Medicines Discovery and Development. Patrick joined the company in 2006 as Head of Drug Discovery. He focused the organisation on science that has the best chance of leading to new medicines, and created small, multidisciplinary teams called Discovery Performance Units. He is transforming the way in which we approach late stage clinical trial design and execution. Prior to joining GSK Patrick was a clinical academic at University College London. Patrick is a member of the Board of the Agency for Science, Technology & Research (A*STAR) and is a director of Genome Research Limited.

Emma Walmsley

Ms. Emma Walmsley is President - Consumer Healthcare Worldwide of GlaxoSmithKline PLC., since October 2011. After joining GSK in May 2010 as President of Consumer Healthcare Europe. Under Emma’s leadership the business has a new strategic direction to become the first and best Fast Moving Consumer Healthcare company, driven by science and values, combining the very best of GSK’s scientific knowledge with the speed and marketing excellence of the Fast Moving Consumer Goods world. Prior to joining GSK, Emma worked with L’Oreal for 17 years where she held a variety of marketing and general management roles in Paris, London and New York. From 2007 she was based in Shanghai as General Manager, Consumer Products, L’Oreal China. She has a degree in Classics and Modern Languages from Oxford University.

Daniel Troy

Mr. Daniel Troy is Senior Vice President, General Counsel of GlaxoSmithKline PLC., since September 2008. He was previously a Partner at the Washington law firm Sidley Austin LLP, where he represented mainly pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations. Dan was formerly Chief Counsel for the FDA, where he served as a primary liaison to the White House and the US Department of Health and Human Services. Dan is a graduate from Cornell University’s School of Industrial and Labor Relations, and earned his law degree from Columbia University School of Law.

Claire Thomas

Ms. Claire Thomas is Senior Vice President - Human Resources of GlaxoSmithKline PLC., since May 2008. She is responsible for GSK’s Environmental Sustainability Strategy. She was previously Senior Vice President, Human Resources, Pharmaceuticals International. Claire joined the company in 1996 and was appointed Senior Vice President, Human Resources, and Pharmaceuticals Europe in 2001, where she successfully led the HR function through the merger. Prior to joining the company she worked for Ford Motor Company, holding various positions in Human Resources. Claire has a Bachelor of Science degree in Economics, Management and Industrial Relations from the University of Wales. Claire was honoured as an Outstanding European Woman of Achievement in 2007.

Bill Louv

Mr. Bill Louv is Senior Vice President - Core Business Services of GlaxoSmithKline Plc. He was appointed to create and lead Core Business Services (CBS) in April 2010. CBS integrates the shared services of the global support functions. He was previously Chief Information Officer. Bill joined the company in 1994 as Vice President of Medical Data Sciences, and has held a number of increasingly senior roles in R&D and IT. Bill has a Bachelor of Science degree in Biology from the College of William and Mary, and Master of Science and Doctor of Philosophy degrees in Statistics from the University of Florida.

Phil Thomson

Mr. Phil Thomson is Senior Vice President - Global Communications of GlaxoSmithKline PLC., since August 2010. He has responsibility for Media Relations, Investor Relations, Corporate Responsibility, Internal Communications and Product Communications. Phil joined Glaxo Wellcome as a commercial trainee in 1996, moving from pharmaceutical brand marketing to product communications. In 1999 he became a Director of Media Relations for Glaxo Wellcome plc and in 2001, took up the position of Director, Investor Relations for GSK. In 2004, he returned to Corporate Media Relations as Vice President. Phil earned his degree in English and History from Durham University.

David Redfern

Mr. David Redfern is Chief Strategy Officer of GlaxoSmithKline PLC. He is responsible for proactive exploration of new business opportunities, strategic planning and the leadership of the dermatology business. In addition to his current role, he was appointed Chairman of the Board of ViiV Healthcare Ltd. in April 2011. Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK’s pharmaceutical businesses in that region and prior to that Senior Vice President for Central and Eastern Europe. David joined the company in 1994 and held a series of finance roles before becoming Finance Director of the European business from 1999-2002. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

Victoria Whyte

Ms. Victoria L. Whyte is Company Secretary of GlaxoSmithKline PLC., since 1 January 2011. She is a solicitor and a Fellow of the Institute of Chartered Secretaries and Administrators. Victoria was formerly Deputy Secretary and Secretary to the Remuneration Committee. She has acted as Secretary to the Board and all the Board’s Committees since her appointment as Company Secretary on 1 January 2011.

Roy Anderson

Professor Sir Roy Malcolm Anderson is Non-Executive Independent Director of GlaxoSmithKline Plc., since 1 October 2007. He is a world-renowned medical scientist with advanced knowledge of infectious disease epidemiology and is currently Professor of Infectious Disease in the Faculty of Medicine, Imperial College, London. He is a fellow and member of the Policy Advisory Board of the Royal Society, and fellow of the Academy of Medical Sciences and the Royal Statistical Society. He is an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences and the French Academy of Sciences. Professor Sir Roy’s background enables him to bring scientific experience to the Board’s deliberations. Professor Sir Roy is a member of the International Advisory Board of Holdingham Group and he is a Trustee of the Natural History Museum, London. He is also a member of the Vaccine International Advisory Board (VACCIAB) of AJ Pharma Holding Sdn. Bhd in Malaysia.

Stephanie Burns

Dr. Stephanie Ann Burns is Non-Executive Independent Director of GlaxoSmithKline PLC., since 12 February 2007. Stephanie is a recognised global business leader, having served as Chairman, President and CEO of Dow Corning Corporation until her retirement at the end of 2011. She has a strong scientific background, with a PhD in organic chemistry with an organosilicon specialty, and is an advocate for science education. Stephanie previously sat on the US President’s Export Council and was an Officer of the Society of Chemical Industry, American Section, as well as the past Honorary President of the UK-based parent society. Stephanie was also an Officer and Chairman of the American Chemistry Council. External appointments Stephanie was appointed a Non-Executive Director of Corning Inc. in January 2012 and a Non-Executive Director of Kellogg Company, in February 2014.

Stacey Cartwright

Ms. Stacey Cartwright is Non-Executive Independent Director of Glaxosmithkline Plc. Stacey is a Chartered Accountant and has significant experience of global consumer businesses and of corporate finance. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc until July 2013. Prior to joining Burberry Group plc in 2004, Stacey held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc. The Board has determined that Stacey has recent and relevant financial experience, and agreed that she has the appropriate qualifications and background to be an audit committee financial expert.

Tom de Swaan

Dr. Tom de Swaan is resigned as Non-Executive Independent Director of GlaxoSmithKline PLC., effective 7 May 2015. Tom has had a long and distinguished career in the European banking industry, having been a member of the Managing Board and Chief Financial Officer of ABN AMRO. Tom has held various executive positions at the Dutch Central Bank and was a Non-Executive Director of the Financial Services Authority (now the Financial Conduct Authority) from 2001 to 2007. He was previously a Non-Executive Director of KPMG’s Public Interest Committee and was also Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold. The Board has determined that Tom has recent and relevant financial experience, and agreed that he has the appropriate qualifications and background to be an audit committee financial expert. External appointments Tom is Chairman of the Supervisory Board of Van Lanschot Bankiers and Chairman of the Board of Directors of Zurich Insurance Group. He is also a member of the Supervisory Board of Royal DSM, and a Senior Adviser to Ondra Partners.

Lynn Elsenhans

Ms. Lynn Laverty Elsenhans is an Independent Non-Executive Director of GlaxoSmithKline Plc., since 1 July 2012. She has a wealth of experience of running a global business and significant knowledge of the global markets in which GSK operates. She served as Chair, President and Chief Executive Officer of Sunoco Inc from 2009 to 2012. Prior to joining Sunoco in 2008 as President and Chief Executive Officer, Lynn worked for Royal Dutch Shell which she joined in 1980 and where she held a number of senior roles, including Executive Vice President, Global Manufacturing from 2005 to 2008. Lynn is a Non-Executive Director of Baker Hughes Inc, a director of the Texas Medical Center, and a director of The First Tee of Greater Houston. She is also a Trustee of the United Way of Greater Houston and a Trustee of Rice University.

Judy Lewent

Ms. Judy C. Lewent is Non-Executive Independent Director of Glaxosmithkline Plc., effective May 8, 2014. Judy has extensive knowledge of the global pharmaceutical industry and of corporate finance, having joined Merck & Co. in 1980 and then served as Chief Financial Officer from 1990 to 2007 when she retired. Judy was previously a Non-Executive Director of Purdue Pharma Inc, Napp Pharmaceutical Holdings Limited and certain Mundipharma International Limited companies until 31 December 2014. Judy previously served as a Non-Executive Director of Dell Inc. and Quaker Oats Company. The Board has determined that Judy has recent and relevant financial experience, and agreed that she has the appropriate qualifications and background to be an audit committee financial expert. External appointments Judy is a Non-Executive Director of Thermo Fisher Scientific Inc. and Motorola Solutions Inc. She is also a Trustee of the Rockefeller Family Trust and Chairperson of the Audit Committee of Rockefeller Financial Services, a life member of the Massachusetts Institute of Technology Corporation and a member of the American Academy of Arts and Sciences.

Deryck Maughan

Sir Deryck Charles Maughan is Senior Independent Non-Executive Director of GlaxoSmithKline PLC., effective May 1, 2013. Sir Deryck has a wealth of international corporate and investment banking experience, having previously served as Chairman and Chief Executive Officer of Citigroup International and of Salomon Brothers Inc. He served as Vice Chairman of the New York Stock Exchange from 1996 to 2000. Sir Deryck was a former Senior Adviser to, and Partner of, Kohlberg Kravis Roberts & Co and previously served as a Non- Executive Director of Thomson Reuters. External appointments Sir Deryck is a Non-Executive Director of BlackRock Inc, Trustee of the British Museum and of New York University Langone Medical Center.

Daniel Podolsky

Dr. Daniel K. Podolsky is Non-Executive Independent Director of GlaxoSmithKline PLC., since 1 July 2006. He is a world-renowned researcher who has advanced knowledge of underlying mechanisms of disease and new therapies for gastrointestinal disorders. He was formerly Mallinckrodt Professor of Medicine and Chief of Gastroenterology at Massachusetts General Hospital and Harvard Medical School, and previously served as the Chief Academic Officer of Partners Healthcare System. Daniel’s current responsibilities in leading a large academic medical centre give him relevant insight into healthcare delivery. Daniel brings scientific expertise to the Board and the Audit & Risk Committee’s deliberations. He is President of the University of Texas Southwestern Medical Center and holds the Philip O’Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Institute of Medicine of the US National Academy of Sciences, member of the Board of the Southwestern Medical Foundation and is a Director of Antibe Therapeutics, Inc. He is also a member of the National Academies of Sciences Board on Army Science and Technology.

Urs Rohner

Mr. Urs Rohner has been appointed as Non-Executive Director of GlaxoSmithKline PLC., effective 1 January 2015. Mr Rohner is currently Chairman of Credit Suisse Group AG, one of the world's leading financial services companies. Mr Rohner was appointed Chairman of Credit Suisse in 2011 following a number of senior positions at the company including General Counsel and Chief Operating Officer. Before joining Credit Suisse in 2004, he was Chief Executive Officer and Chairman for four years at ProSiebenSat.1 Group, one of the largest independent media corporations in Europe. This followed a number of years in private practice at major law firms in Switzerland and the USA.

Jing Ulrich

Ms. Jing L. Ulrich has resigned as Independent Non-Executive Director of GlaxoSmithKline Plc., effective 7 May 2015. She is a Managing Director and Vice Chairman of Asia Pacific at JPMorgan Chase. She advises the firm’s most senior global clients across all asset classes, while building relationships with executives at Asia’s leading enterprises. Jing is one of the most prominent advisors to the large global asset management companies, sovereign wealth funds, and multinational corporations. She works with all lines of business at JPMorgan Chase to foster greater cross-border collaboration and strengthen senior client relationships in Asia Pacific and the rest of the world. She was Managing Director and Chair of Global Markets, China at JPMorgan between 2005 and 2013. From 2003 to 2005, Jing worked for Deutsche Bank as Managing Director, Head of Greater China Equities. She previously held financial positions, specialising in the Asia Pacific region, with CLSA Asia Pacific Markets and the Emerging Markets Investors Corporation. She was educated at Harvard and Stanford Universities.

Hans Wijers

Mr. Hans Wijers is an Independent Non-Executive Director at GlaxoSmithKline Plc., effective from April 1, 2013. He has a broad range of business, economic and political experience, having served as Chief Executive Officer and Chairman at Akzo Nobel NV from 2002 to 2012. Hans had a long and distinguished career in academia, public service and strategy consulting. He served as a senior vice president of the Boston Consulting Group from 1998 to 2002. Hans is Chairman of the Supervisory Board of Heineken NV and also Deputy Chairman and Non-Executive Director of Royal Dutch Shell. He is also Chairman of the Supervisory Board of AFC Ajax.
Search Stocks